Innate Pharma (IPH) Corporate presentation summary

Strategic focus and portfolio overview

• Concentrates on three high-value clinical assets: lacutamab, IPH4502, and monalizumab, each targeting significant unmet needs in oncology.

• In-house expertise enables discovery and development of differentiated antibody therapeutics.

• Organization is structured for agile execution and value creation.

Lacutamab: clinical progress and market opportunity

• Lacutamab targets KIR3DL2 in CTCL and PTCL, showing durable activity and favorable tolerability in Phase 2 trials.

• Phase 2 TELLOMAK data in Sézary syndrome (SS) post-mogamulizumab: ORR 42.9%, median DoR 25.6 months, median PFS 8.3 months.

• Phase 3 TELLOMAK-3 trial cleared by FDA, with potential for accelerated approval in SS by 2027.

• Peak year sales potential estimated at over $500 million in CTCL, with a focused US commercial strategy.

• Additional development ongoing in PTCL, with Phase 2 data expected in 2026.

IPH4502: innovation in solid tumors

• IPH4502 is a novel Nectin-4 exatecan ADC, designed to overcome limitations of existing therapies like enfortumab vedotin.

• Demonstrates preclinical efficacy in bladder cancer models resistant to prior Nectin-4 therapies and in tumors with low/moderate Nectin-4 expression.

• Phase 1 trial ongoing in multiple solid tumors, including bladder, breast, NSCLC, and others.

• Addresses significant unmet need in post-EV+P bladder cancer, where no standard of care exists.